Scientific Presentations & Publications

Poster Presentation: A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer

Poster Presentation: A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers

Poster Presentation: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies

Poster Presentation: A Phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer

Poster Presentation: CUE-102 Selectively Activates and Expands WT1-Specific T Cells for the Treatment of Patients with WT1+ Malignancies

Poster Presentation: Integration of IL-2 signaling at the immunological synapse

Collaboration with the laboratory of Michael Dustin at the University of Oxford

Poster Presentation: A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer

Poster Presentation: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies

The Journal of Clinical Investigation; October 21, 2021 DOI: 10.1172/JCI141051

Mengyan Li, Scott J. Garforth, Kaitlyn E. O’Connor, Hang Su, Danica Lee, Alev Celikgil, Rodolfo J. Chaparro, Ronald Seidel, R. Brad Jones, Ravit Arav-Boger, Steven C. Almo and Harris Goldstein

Nature Portfolio, Scientific Reports; September 28, 2021 DOI: 10.1038/s41598-021-98716-z

Ronald D. Seidel, Zohra Merazga, Dharma Raj Thapa, Jonathan Soriano, Emily Spaulding, Ahmet S. Vakkasoglu, Paige Ruthardt, Wynona Bautista, Steven N. Quayle, Peter A. Kiener, Simon Low, John F. Ross, Saso Cemerski, Anish Suri, Steven C. Almo & Rodolfo J. Chaparro

Video: CUE-401: A novel IL-2/TGF-beta fusion protein for the induction of CD4+ FOXP3+ regulatory T cells

Download Poster

Poster Presentation: Immuno-STAT™ (Selective Targeting and Alteration of T cells) Platform: Targeting Tumor Heterogeneity and Tumor Escape Mechanisms

Presentation: Directly Targeting Autoantigen-Specific T cells with Immuno-STATs

Nature Methods 2020; September 14, 2020 DOI: 10.1038/s41592-020-0934-5

Andrew W. Woodham, Stad H. Zeigler, Ella L. Zeyang, Stephen C. Kolifrath, Ross W. Cheloha, Mohammad Rashidian, Rodolfo J. Chaparro, Ronald D. Seidel, Scott J. Garforth, Jason L. Dearling, Maia Mesyngier, Phaneendra K. Duddempudi, Alan B. Packard, Steven C. Almo & Hidde L. Ploegh

Video Poster Presentation: Neo-STAT™: A new biologics platform for selective targeting of tumor-specific T cells with enhanced antigen modularity

PLOS One 2020; June 4, 2020 DOI: 10.1371/Journal PONE.0233578

Sarah C. Garrett-Thomson, Aldo Massimi, Elena V. Fedorov, Jeffrey B. Bonanno, Lisa Scandiuzzi, Brandan Hillerich, Ronald D. Seidel, III, James D. Love, Scott J. Garforth, Chandan Guha, Steven C. Almo

Clinical Cancer Research 2020; January 21, 2020 DOI: 10.1158/1078-0432.CCR-19-3354

Steven N Quayle, Natasha Girgis, Dharma R Thapa, Zohra Merazga, MelissaM Kemp, Alex Histed, Fan Zhao, Miguel Moreta, Paige Ruthardt, Sandrine Hulot, Alyssa Nelson, Lauren D Kraemer, Dominic R Beal, Luke Witt, Jessica Ryabin, Jonathan Soriano, Mark Haydock, Emily Spaulding, John F Ross, PeterA Kiener, Steven Almo, Rodolfo Chaparro, Ronald Seidel, Anish Suri, Saso Cemerski, Kenneth J. Pienta and Mary Ellen Simcox

Poster Presentation: CUE-101, a Novel HPV16 E7:pMHC:IL-2:Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies

Video: Diagnostic & disease detection to transform biopharma

Poster Presentation: CUE-101, a novel Fc fusion protein for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies